Chemomab Therapeutics (CMMB) Other Non-Current Assets (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Other Non-Current Assets came in at $211000.0 in Q4 2025, down 45.19% YoY from $385000.0 in Q4 2024, and down 16.93% on a QoQ basis from $254000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Other Non-Current Assets data on file, last reported at $211000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 45.19% year-over-year to $211000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $211000.0 (down 45.19% YoY) and the FY2025 annual result came in at $211000.0, down 45.19% from the prior year.
- Other Non-Current Assets retreated to $211000.0 in Q4 2025, from $254000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $995000.0 in Q2 2021 to a low of $51000.0 in Q1 2021.
- A 5-year average of $575150.0 and a median of $581000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets jumped 1850.98% — and 2025, when it slumped 45.19%.
- Tracing CMMB's Other Non-Current Assets over 5 years: stood at $908000.0 in 2021, then declined by 19.27% to $733000.0 in 2022, then retreated by 23.74% to $559000.0 in 2023, then sank by 31.13% to $385000.0 in 2024, then slumped by 45.19% to $211000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $211000.0 (Q4 2025), $254000.0 (Q3 2025), and $298000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 211,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | 298,000.00 |
| Mar 31, 2025 | 341,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Jun 30, 2024 | 472,000.00 |
| Mar 31, 2024 | 516,000.00 |
| Dec 31, 2023 | 559,000.00 |
| Sep 30, 2023 | 603,000.00 |
| Jun 30, 2023 | 646,000.00 |
| Mar 31, 2023 | 690,000.00 |
| Dec 31, 2022 | 733,000.00 |
| Sep 30, 2022 | 776,000.00 |
| Jun 30, 2022 | 821,000.00 |
| Mar 31, 2022 | 864,000.00 |
| Dec 31, 2021 | 908,000.00 |
| Sep 30, 2021 | 952,000.00 |
| Jun 30, 2021 | 995,000.00 |
| Mar 31, 2021 | 51,000.00 |